Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01993212 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
A Phase 3 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT01993212 is a Phase 3 study that has completed, run by Repros Therapeutics. The registered enrollment target is 120 participants.
The verdict
NCT01993212, a Phase 3 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
This is a Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men with Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment with the 12.5 mg or 25 mg Androxal or AndroGel 1.62%.
Interventions
- DRUG Placebo Capsules
- DRUG Placebo Gel
- DRUG AndroGel 1.62%
- DRUG Androxal 12.5 mg or 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01993212
The ClinicalTrials.gov registry entry for NCT01993212 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Capsules is the first listed.
NCT01993212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01993212 about?
NCT01993212 is a clinical study titled "A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%". This is a Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men with Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment with the 12.5 mg or 25 mg Androxal or AndroGel 1.62%.
What is the current status of trial NCT01993212?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2014-01. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01993212?
The interventions under investigation include: Placebo Capsules (DRUG), Placebo Gel (DRUG), AndroGel 1.62% (DRUG), Androxal 12.5 mg or 25 mg (DRUG).
Who is sponsoring clinical trial NCT01993212?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.